Acute myocarditis caused by COVID-19 disease and following COVID-19 vaccination

Area of Science:

• Cardiology
• Infectious Diseases
• Vaccinology

Background:

• Myocarditis and pericarditis are heart inflammatory conditions presenting with chest pain, fatigue, and palpitations.
• These conditions are linked to SARS-CoV-2 infection and may contribute to COVID-19 mortality.
• mRNA COVID-19 vaccines (Comirnaty, Spikevax) have been associated with rare cases of myocarditis and pericarditis, particularly after the second dose.

Purpose of the Study:

• To review the latest findings on myocarditis and pericarditis following COVID-19 vaccination.
• To discuss considerations for the diagnosis and management of these rare cardiac conditions.
• To inform healthcare providers and the public about the risk-benefit profile of COVID-19 vaccines.

Main Methods:

• Review of recent data and regulatory assessments from the FDA and EMA.
• Analysis of the clinical spectrum and incidence of vaccine-associated myocarditis and pericarditis.
• Synthesis of current knowledge on diagnosis and management strategies.

Main Results:

• Myocarditis and pericarditis following mRNA COVID-19 vaccination are determined to be 'very rare' events (~1 in 10,000).
• Younger males exhibit the highest risk among vaccinated populations.
• Regulatory agencies (FDA, EMA) confirm that vaccine benefits significantly outweigh the risks.

Conclusions:

• Despite rare risks of myocarditis and pericarditis, COVID-19 vaccines remain essential for preventing severe illness.
• Early recognition and appropriate management are key for patients diagnosed with these conditions.
• Ongoing monitoring and research are important for understanding and mitigating rare vaccine side effects.